Qure's AMT-130 shows promising results for Huntington’s disease. Learn why QURE stock faces commercialization challenges ...
UniQure (QURE) stock shot up 90% on news the company had reached an agreement with the FDA on an accelerated approval pathway ...
William Blair analyst Sami Corwin has maintained their bullish stance on QURE stock, giving a Buy rating today.Pick the best stocks and ...
Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on uniQure (QURE – Research Report). The associated price target ...
U.S. Food and Drug Administration (FDA) agrees that data from ongoing Phase I/II studies compared to a natural history external control may serve as the primary basis for a Biologics License ...
Qure stock rallies 110% on reaching alignment with the FDA on key elements of an accelerated approval pathway for AMT-130 to ...
In a Type B meeting, the FDA signified that it will allow uniQure to use a natural history control, the composite Unified ...
Qure stock surges after FDA agrees on an accelerated approval pathway for its Huntington's disease treatment, AMT-130.
The company now says that, during a recent meeting with the FDA, the two parties agreed on some key elements for an ...
Dutch gene therapy company uniQure saw its shares rocket 86% to $13.57 today, after it reached agreement with the US Food and ...
Qure has reached an agreement with the U.S. Food and Drug Administration (FDA) on key elements of an Accelerated Approval pathway for AMT-130, its gene therapy treatment aimed at Huntington’s disease.
Crucially for the Netherlands-based biopharma company, the FDA has said that the composite Unified Huntington's Disease ...